Charles G. Drake
Director/Board Member at Kleo Pharmaceuticals, Inc.
Charles G. Drake active positions
Companies | Position | Start | End |
---|---|---|---|
The Johns Hopkins University | Corporate Officer/Principal | - | - |
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Director/Board Member | - | - |
Career history of Charles G. Drake
Former positions of Charles G. Drake
Companies | Position | Start | End |
---|---|---|---|
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Founder | - | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Founder | 2009-08-27 | - |
Corporate Officer/Principal | 2006-12-31 | 2009-08-27 |
Training of Charles G. Drake
The University of Colorado | Doctorate Degree |
Statistics
International
United States | 7 |
Operational
Corporate Officer/Principal | 3 |
Founder | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Health Technology |
Potenza Therapeutics, Inc.
Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Commercial Services |
Tizona Therapeutics, Inc.
Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Charles G. Drake
- Experience